Yang, James C.
National Institutes of Health · National Cancer Institute
7 papers on CoChatORCID 0000-0001-8935-5008
Most cited papers
- Verified
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 1,595
- Verified
Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 569
- Verified
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research
Immunotherapy and Immune ResponsesCAR-T cell therapy research
Cited by 240
- Verified
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell
Cancer Immunotherapy and BiomarkersCAR-T cell therapy research
Cited by 200
- Verified
Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma
Kochenderfer, J. N., Somerville, R., Lu, L., Iwamoto, A., Yang, J. C., Klebanoff, C., Kammula, U., Sherry, R. M., Victoria, S., Yuan, C., et al. (2014) · Blood
CAR-T cell therapy researchLymphoma Diagnosis and Treatment
Cited by 33
- Verified
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 16
- Verified
Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity
Mikkilineni, L., Manasanch, E. E., Natrakul, D., Brudno, J. N., Mann, J., Goff, S. L., Yang, J. C., Lam, N., Maric, I., Stetler-Stevenson, M., et al. (2021) · Blood
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free